MNOV
MediciNova, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.63
+0.62%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−5.0x
Market Cap
$80.23M
MomentumView details →
1D Return
+0.62%
YTD Return
+20.61%
RSI (14)
65.3
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−5.0x
Market Cap
$80.23M
RSI (14)
65.3
MomentumView details →
1D Return
+0.62%
YTD Return
+20.61%
SummaryUpdated Jun 1, 2026
MediciNova, Inc. (NASDAQ:MNOV) is a biopharmaceutical company founded in 2000 and headquartered in La Jolla, California. The company went public in December 2006 and focuses on developing novel small molecule therapeutics for serious diseases with significant unmet medical needs. MediciNova operates as a clinical-stage biotechnology company with no marketed products, relying on its pipeline of drug candidates in various stages of development across multiple therapeutic areas including neurology, respiratory diseases, and oncology.
Similar companies
Latest newsMore news →
MediciNova Inc. announced the appointment of Yuichi Iwaki as President and Chief Executive Officer and Kazuko Matsuda as Chief Medical Officer, effective August 17, 2026, with compensation packages including base salaries and severance terms.17d agoMediciNova reported a Q2 2026 net loss of $0.05 per share, narrower than the Zacks Consensus Estimate of a $0.06 loss and improved from a $0.07 loss a year earlier.22d ago